During the past decade, Gemeinschaftspraxis conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gemeinschaftspraxis" #1 sponsor was "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials, followed by "Karolinska University Hospital" with 1 trials sponsored, "Pfizer" with 1 trials sponsored, "Prof. Dr. Nikolas von Bubnoff" with 1 trials sponsored and "Prof. Wolfgang Janni" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gemeinschaftspraxis" #1 collaborator was "Austrian Breast & Colorectal Cancer Study Group" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator, "Novartis" with 1 trials as a collaborator and "Swedish Breast Cancer Group" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Gemeinschaftspraxis" are "Breast Cancer" (1 trials), "Breast Neoplasms" (1 trials), "Chronic Myeloid Leukemia" (1 trials), "HER2-negative Metastatic Breast Cancer" (1 trials) and "Hormone Receptor-positive Metastatic Breast Cancer" (1 trials). Many other conditions were trialed in "Gemeinschaftspraxis" in a lesser frequency.

Most popular intervention types in "Gemeinschaftspraxis" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib + Aromatase Inhibitor" (1 trials), "Abemaciclib + Fulvestrant" (1 trials), "FEC→T" (1 trials), "Imatinib" (1 trials) and "Nilotinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gemeinschaftspraxis" are 3 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Gemeinschaftspraxis". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Gemeinschaftspraxis, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Gemeinschaftspraxis, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".